Atlas Trials

Women's Cancer Study Group GmbH

20 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Women's Cancer Study Group GmbH

RecordFirmDate
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer (NCT07178730)Women's Cancer Study Group GmbH2026-08-30
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment (NCT07281833)Women's Cancer Study Group GmbH2025-11-27
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (NCT06081244)Women's Cancer Study Group GmbH2024-10-10
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (NCT05704829)Women's Cancer Study Group GmbH2024-02-05
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS (NCT05792150)Women's Cancer Study Group GmbH2022-12-07
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) (NCT03988036)Women's Cancer Study Group GmbH2020-08-18
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (NCT04055493)Women's Cancer Study Group GmbH2019-07-02

Track Women's Cancer Study Group GmbH automatically

Every clearance here is in the API, with alerts when new ones post.